GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas.

GSK is redesigning pharmaceutical research around AI, from data infrastructure to autonomous scientific agents. Its platforms ...

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk: London, UK Tuesday, May 19, 2026, 12:00 Hrs [IST] GSK plc announced tha ...

By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Seeking to build up its ...

GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...

GSK plc (NYSE:GSK) ranks among the best low-risk investments in May 2026. GSK plc (NYSE:GSK) stated on April 15 that it had ...

GSK has disclosed a series of routine share dealings by senior executives under its Share Reward Plan, with ordinary shares acquired on 12 May 2026 on the London Stock Exchange. Participants include ...

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

This deal strengthens GSK’s focus on addressing the complications of obesity, while restocking the company’s pipeline amid ...

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its ...

LSE:GSK Earnings and Revenue History May 6th 2026 How Do Unusual Items Influence Profit? Importantly, our data indicates that ...